company background image
22Z logo

Zealand Pharma DB:22Z Stock Report

Last Price

€96.25

Market Cap

€5.9b

7D

2.0%

1Y

216.8%

Updated

25 Mar, 2024

Data

Company Financials +

22Z Stock Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.

22Z fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Zealand Pharma A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Pricekr.96.25
52 Week Highkr.103.40
52 Week Lowkr.27.20
Beta0.68
1 Month Change50.86%
3 Month Change93.04%
1 Year Change216.82%
3 Year Change257.54%
5 Year Change494.50%
Change since IPO946.99%

Recent News & Updates

Recent updates

Shareholder Returns

22ZDE BiotechsDE Market
7D2.0%3.3%1.6%
1Y216.8%35.8%6.4%

Return vs Industry: 22Z exceeded the German Biotechs industry which returned 35.3% over the past year.

Return vs Market: 22Z exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is 22Z's price volatile compared to industry and market?
22Z volatility
22Z Average Weekly Movement16.6%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 22Z's share price has been volatile over the past 3 months.

Volatility Over Time: 22Z's weekly volatility has increased from 10% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997253Adam Steensberghttps://www.zealandpharma.com

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
22Z fundamental statistics
Market cap€5.86b
Earnings (TTM)-€94.36m
Revenue (TTM)€45.96m

127.5x

P/S Ratio

-62.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
22Z income statement (TTM)
Revenuekr.342.79m
Cost of Revenuekr.688.10m
Gross Profit-kr.345.31m
Other Expenseskr.358.43m
Earnings-kr.703.74m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 16, 2024

Earnings per share (EPS)-11.31
Gross Margin-100.74%
Net Profit Margin-205.30%
Debt/Equity Ratio0%

How did 22Z perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.